LexDanaLexDanabeta
Inventor

William Marshall

Inventor
Boulder, CO, US

Overview

133→
Patents
1994–2020
Patent span
Chemistry
Primary field (CPC C)

Patents· 133 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C12Nprimary
C12NMicroorganisms or enzymes29%
G16BBioinformatics, i.e. information and communication technology [ict] specially adapted for genetic or protein-related data processing in computational molecular biology23%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations21%
A61KPreparations for medical, dental or toiletry purposes12%
C12YEnzymes11%
C07HSugars3%
C07KPeptides1%
G06FElectric digital data processing0%
C07JSteroids0%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms0%
PatentTitleYear
10,765,695Methods and compositions for selecting siRNA of improved functionality202010,696,968Methods and compositions for selecting siRNA of improved functionality202010,421,970Methods and compositions for selecting siRNA of improved functionality201910,233,449Methods and compositions for selecting siRNA of improved functionality201910,011,836Methods and compositions for selecting siRNA of improved functionality20189,879,266'Methods and compositions for selecting siRNA of improved functionality'20189,839,649'Methods and compositions for selecting siRNA of improved functionality'20179,777,270'Methods and compositions for selecting siRNA of improved functionality'20179,771,586'RNAi targeting ZNF205'20179,719,092'RNAi targeting CNTD2'20179,719,094'RNAi targeting SEC61G'20179,416,360'Base modified oligonucleotides'20169,228,186'Methods and compositions for selecting siRNA of improved functionality'20169,012,225'Lipophilic polynucleotide conjugates'20158,937,172'siRNA targeting catenin, beta-1 (CTNNB1)'20158,907,077'siRNA targeting TIE-2'20148,883,998'siRNA targeting myeloid differentiation primary response gene (88) (MYD88)'20148,658,784'siRNA targeting amyloid beta (A4) precursor protein (APP)'20148,658,785'siRNA targeting tie-2'20148,642,751'MicroRNA inhibitors comprising locked nucleotides'20148,633,306'SiRNA targeting histamine receptor H1'20148,575,329'siRNA targeting kinase insert domain receptor (KDR)'20138,461,326'SiRNA targeting connective tissue growth factor (CTGF)'20138,445,667'SiRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)'20138,445,668'SiRNA targeting apolipoprotein (APOB)'20138,426,579'SiRNA targeting myeloid differentiation primary response gene (88) (MYD88)'20138,399,654'siRNA targeting catenin, Beat-1 (CTNNB1)'20138,314,229'siRNA targeting tie-2'20128,304,528'SiRNA targeting fructose-1, 6-bisphosphatase 1 (FBP1)'20128,293,887'SiRNA targeting beta secretase (BACE)'20128,273,722'Enhanced biotherapeutic production using inhibitory RNA'20128,268,985'siRNA targeting amyloid beta (A4) precursor protein (APP)'20128,247,169'SiRNA targeting diacylglycerol O-acyltransferase homolog 2 (DGAT2)'20128,236,942'SiRNA targeting glucagon receptor (GCGR)'20128,232,385'siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)'20128,232,386'SiRNA targeting apolipoprotein B (APOB)'20128,222,395'siRNA targeting kinase insert domain receptor (KDR)'20128,222,396'SiRNA targeting proto-oncogene MET'20128,217,162'siRNA targeting interleukin-1 receptor-associated kinase 4(IRAK4)'20128,198,427'SiRNA targeting catenin, beta-1 (CTNNB1)'20128,138,329'siRNA targeting connective tissue growth factor (CTGF)'20128,093,370'siRNA targeting spleen tyrosine kinase'20128,090,542'Functional and hyperfunctional siRNA'20128,071,754'siRNA targeting apolipoprotein B (APOB)'20118,067,576'siRNA targeting serine/threonine kinase 12 (STK12 or aurora B kinase)'20118,039,610'siRNA targeting superoxide dismutase 1 (SOD1)'20118,030,476'siRNA targeting gremlin'20118,030,474'siRNA targeting cyclin-dependent kinase 4 (CDK4)'20118,022,199'SiRNA targeting myeloid differentiation primary response gene (88) (MYD88)'20118,022,198'siRNA targeting histamine receptor H1'20118,013,145'SiRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)'20118,008,474'siRNA targeting KRAS'20118,000,902'Methods and compositions for selecting siRNA of improved functionality'20117,999,097'siRNA targeting beta secretase (BACE)'20117,985,854'siRNA targeting TATA box binding protein (TBP)-associated factor (TAF1)'20117,977,471'siRNA targeting TNFα'20117,951,935'siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC)'20117,935,813'siRNA target hypoxia-inducible factor 1'20117,935,811'Apparatus and system having dry gene silencing compositions'20117,923,206'Method of determining a cellular response to a biological agent'20117,923,207'Apparatus and system having dry gene silencing pools'20117,897,754'SiRNA targeting ras-related nuclear protein RAN'20117,893,247'siRNA targeting spleen tyrosine kinase'20117,855,186'siRNA targeting TIE-2'20107,833,989'siRNA targeting connective tissue growth factor (CTGF)'20107,834,171'Modified polynucleotides for reducing off-target effects in RNA interference'20107,834,170'Functional and hyperfunctional siRNA'20107,829,696'siRNA targeting amyloid beta (A4) precursor protein (APP)'20107,820,809'Functional and hyperfunctional siRNA directed against Bcl-2'20107,816,512'siRNA targeting proto-oncogene MET'20107,807,820'siRNA targeting beta secretase (BACE)'20107,807,819'siRNA targeting survivin'20107,803,933'siRNA targeting TATA box binding protein (TBP)-associated factor (TAF1)'20107,795,421'siRNA targeting apolipoprotein B (APOB)'20107,795,420'Functional and hyperfunctional siRNA directed against Bcl-2'20107,781,575'siRNA targeting tumor protein 53 (p53)'20107,745,610'siRNA targeting cyclin dependent kinase 11 (CDK11)'20107,745,611'siRNA targeting KRAS'20107,745,612'siRNA targeting interleukin-1 receptor-associated kinase 4 (IRAK4)'20107,741,470'siRNA targeting gremlin'20107,737,267'siRNA targeting hypoxia-inducible factor 1'20107,709,629'siRNA targeting diacylglycerol O-acyltransferase homolog 2 (DGAT2)'20107,696,344'siRNA targeting complement factor B'20107,691,997'Functional and hyperfunctional siRNA'20107,691,998'siRNA targeting nucleoporin 62kDa (Nup62)'20107,678,896'siRNA targeting serine/threonine kinase 12 (STK12 or aurora B kinase)'20107,674,896'siRNA targeting BCL2L1'20107,666,853'siRNA targeting connective tissue growth factor (CTGF)'20107,662,950'siRNA targeting myeloid differentiation primary response gene (88) (MYD88)'20107,655,788'siRNA targeting DNA-damage-inducible transcript 4 (DDIT4)'20107,655,789'siRNA targeting transient receptor potential cation channel, subfamily V, member 1 (TRPV1)'20107,645,870'siRNA targeting proteasome 26S subunit, non-ATPase, 10 (Gankyrin or PSMD10)'20107,645,869'siRNA targeting spleen tyrosine kinase'20107,642,349'siRNA targeting TATA box binding protein (TBP)-associated factor (TAF1)'20107,638,621'siRNA targeting insulin-like growth factor 1 receptor (IGF-1R)'20097,638,622'SiRNA targeting intercellular adhesion molecule 1 (ICAM1)'20097,635,771'siRNA targeting amyloid beta (A4) precursor protein (APP)'20097,635,770'siRNA targeting protein kinase N-3 (PKN-3)'20097,632,938'siRNA targeting superoxide dismutase 1 (SOD1)'20097,632,939'siRNA targeting proto-oncogene MET'20097,619,081'siRNA targeting coatomer protein complex, subunit beta 2 (COPB2)'20097,615,541'siRNA targeting TIE-2'20097,612,196'siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)'20097,608,707'siRNA targeting survivin'20097,608,706'siRNA targeting ras-related nuclear protein'20097,605,250'siRNA targeting cAMP-specific phosphodiesterase 4D'20097,605,252'siRNA targeting kinase insert domain receptor (KDR)'20097,598,369'siRNA targeting histamine receptor H1'20097,598,370'siRNA targeting polo-like kinase-1 (PLK-1)'20097,595,387'Modified polynucleotides for reducing off-target effects in RNA interference'20097,595,389'siRNA targeting casitas B cell lymphoma-B (CBL-B)'20097,595,388'siRNA targeting EPH receptor A3 (EPHA3)'20097,592,443'siRNA targeting interleukin-1 receptor-associated kinase 4 (IRAK4)'20097,592,442'siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2)'20097,592,444'siRNA targeting myeloid cell leukemia sequence 1'20097,589,191'siRNA targeting hypoxia-inducible factor 1'20097,582,746'siRNA targeting complement component 3 (C3)'20097,582,747'siRNA targeting inner centromere protein antigens (INCENP)'20097,579,457'siRNA targeting carbonic anhydrase II'20097,579,458'siRNA targeting synuclein, alpha (SNCA-1)'20097,576,197'SiRNA targeting KRAS'20097,576,196'siRNA targeting transducin (beta)-like 3 (TBL3)'20097,569,684'siRNA targeting gremlin'20097,550,572'siRNA targeting cell division cycle 20 homolog (CDC20)'20097,541,453'siRNA targeting aquaporin 4'20097,521,191'siRNA targeting connexin 43'20097,514,550'siRNA targeting myeloid cell leukemia sequence 1'20097,511,132'Functional and hyperfunctional siRNA directed against Bcl-2'20097,507,811'siRNA targeting KRAS'20096,677,136'Glucagon antagonists'20045,695,979'Inhibition of reverse transcriptase by phosphorodithioates'19975,453,496'Polynucleotide phosphorodithioate'19955,278,302'Polynucleotide phosphorodithioates'1994

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1994–2020Based in Boulder, CO, US· patent location history
2009–2013Patents assigned to DHARMACON INC (107)· patent assignee history
2011–2014Patents assigned to LEAKE DEVIN (27)· patent assignee history
2011–2014Patents assigned to MARSHALL WILLIAM (27)· patent assignee history
2011–2014Patents assigned to REYNOLDS ANGELA (27)· patent assignee history
2011–2014Patents assigned to KHVOROVA ANASTASIA (26)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
DHARMACON INC1072009–2013
LEAKE DEVIN272011–2014
MARSHALL WILLIAMself272011–2014
REYNOLDS ANGELA272011–2014
KHVOROVA ANASTASIA262011–2014
Locations
LocationPatentsSpan
Boulder, CO, US1331994–2020